Abstract:Twenty-five to thirty percent of patients with node-negative breast cancer are expected to relapse following surgery, therefore great efforts have been made to identify new prognostic markers that could be useful in defining patients for additional therapy. The expression of MMP-2 and MMP-9 has been associated with high potential of metastasis in several human carcinomas including breast cancer. In the present study we examined the prognostic value of immunoreactive MMP-2/MMP-9 protein in 270 consecutive lymph node negative cases who received radical mastectomy or modified radical mastectomy. Among the patients, 211 cases received adjuvant endocrine therapy and/or adjuvant chemotherapy. Using immunohistochemical assay, we found that 56.7% of the resected tumors were positive for MMP-2 whereas 59.6% of the samples were positive for MMP-9. χ 2 test demonstrated a significant direct association between MMP-2 and MMP-9 ( p < 0.001); positive immunostaining of MMP-2 was significantly related to higher tumor grade ( p < 0.001) and larger tumor size ( p =0.012); positive immunostaining of MMP-9 was significantly related to higher tumor grade ( p =0.002). In univariate analysis, using Cox-proportional hazard model we found MMP-2, MMP-9 and the co-expression of MMPs (MMP2/MMP9) were significantly associated with patients' relapse free survival ( p =0.016, 0.015 and 0.013 respectively) but not overall survival ( p =0.122, 0.320 and 0.091 respectively). Log-rank test also showed that MMP-2, MMP-9 or the co-expression of MMP2/MMP9 was unfavorable prognostic factor for relapse free survival but not overall survival. In subgroup analysis, we found MMPs were more prognostic for patients with no adjuvant treatment than for patients with adjuvant therapy. In multivariate analysis, using Cox-proportional hazard model we found co-expression of MMPs, larger tumor size and higher tumor grade were unfavorable for relapse free survival ( p =0.038, 0.007 and 0.015 for each). We concluded that MMP-2 and MMP-2 are unfavorable prognostic factors in breast cancer patients. They might be potential predictive factor for adjuvant systemic therapy. The co-expression of MMP-2 and MMP-9 has significantly prognostic value in node-negative patients.

Upregulated Matrix Metalloproteinase-2 and Downregulated Tissue Factor Pathway Inhibitor-2 Are Risk Factors for Lymph Node Metastasis and Perineural Invasion in Pancreatic Carcinoma.

Increased Matrix Metalloproteinase-2 Expression and Reduced Tissue Factor Pathway Inhibitor-2 Expression Correlate with Angiogenesis and Early Postoperative Recurrence of Pancreatic Carcinoma.

Correlation and Prognostic Significance of MMP-2 and TFPI-2 Differential Expression in Pancreatic Carcinoma.

The Expression and Clinical Significance of Matrix Metalloproteinase-2 in Human Pancreatic Carcinoma.

Expression of C-Myc and Fas Correlates with Perineural Invasion of Pancreatic Cancer.

The expressions and significance of MMP-2 and TIMP-2 in human pancreatic carcinoma

High-Level Expression and Prognostic Significance of Matrix Metalloprotease-19 and Matrix Metalloprotease-20 in Human Pancreatic Ductal Adenocarcinoma

Activation of the Wnt pathway through Wnt2 promotes metastasis in pancreatic cancer.

Expressions of Matrix Metalloproteinase-2 and -9 in Pancreatic Carcinoma and Its Significance

Prognostic significance of tissue factor pathway inhibitor-2 in pancreatic carcinoma and its effect on tumor invasion and metastasis

The Expression and Significance of MMP-2 in Human Pancreatic Carcinoma

Relationship of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression with clinicopathological properties of human gastric cancer

Expression of Matrix Metalloproteinase-9 and Pigment Epithelium-Derived Factor and Their Correlation with Tumor Invasion and Lymph Node Metastasis in Pancreatic Carcinoma

Relationship between matrix metalloproteinase-2 mRNA expression and clinicopathological and urokinase-type plasminogen activator system parameters and prognosis in human gastric cancer

Elevated serum MMP-1 associated with advanced disease stage and lymph node metastasis in patients with pancreatic carcinoma

Prognostic Value of Matrix Metalloproteinases (MMP-2 and MMP-9) in Patients with Lymph Node-Negative Breast Carcinoma

Relationships Between Expressions of MMP-2, MMP-9, TIMP-1 in Gastric Carcinoma and Pathological Characteristics and Prognosis

Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in colorectal carcinoma invasion and metastasis

Overexpression of Membrane-Type 2 Matrix Metalloproteinase Induced by Hypoxia-Inducible Factor-1Α in Pancreatic Cancer: Implications for Tumor Progression and Prognosis.

Angiopoietin-2,MMP-9 and TIMP-1 Expressions in Pancreatic Cancer and Their Relations to Invasiveness and Metastasis